Mylan's (MYL) EpiPen is going to start selling a generic version of its EpiPen allergy treatment with more than a 50% discount. The move follows 20 states filed a lawsuit against the drugmaker along with a US government investigation.
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.